• Home
  •  / Jasper Therapeutics

Jasper Therapeutics

OverviewSuggest Edit

Jasper is a biotechnology company focused on enabling safer conditioning agents that expand the application of curative hematopoietic stem cell transplants and gene therapies. The company's lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.

TypePrivate
Websitejaspertherapeu.wpengine.com

Recent NewsAll News

Latest Updates

Cybersecurity ratingFMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Jasper Therapeutics

Jeet Mahal

Jeet Mahal

Chief Financial and Business Officer
Judith Shizuru

Judith Shizuru

Director
Kevin Heller

Kevin Heller

Executive Vice President, Research and Development
Carol Zoltowski

Carol Zoltowski

Senior Vice President, Regulatory Affairs and Quality
Janet Hurt

Janet Hurt

Vice President, Clinical Operations
Show more

Jasper Therapeutics Financials and Metrics

Summary Metrics

Jasper Therapeutics total Funding

$49.1 m

Jasper Therapeutics latest funding size

$14.1 m

Time since last funding

2 years ago

Jasper Therapeutics investors

Roche Venture Fund, Abingworth, Alexandria Venture Investments, Quiming Venture Partners USA, Supervisor Capital
Jasper Therapeutics's latest funding round in January 2020 was reported to be $14.1 m. In total, Jasper Therapeutics has raised $49.1 m
Show all financial metrics

Jasper Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

F

56/100

Learn more about our premium products
SecurityScorecard logo

Jasper Therapeutics Online and Social Media Presence

Jasper Therapeutics's Trends

Embed Graph

Jasper Therapeutics News and Updates

November 12, 2021

Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results for the quarter ended September 30, 2021, and provided a business update.
November 09, 2021

Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy

REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to eva…
November 08, 2021

Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annua…
September 22, 2021

Amplitude Healthcare Acquisition Corporation Announces Shareholder Approval of Business Combination with Jasper Therapeutics, Inc.

Exhibit 99.1

 Jasper Therapeutics Frequently Asked Questions

  • Who are Jasper Therapeutics key executives?

    Jasper Therapeutics's key executives are Jeet Mahal, Judith Shizuru and Kevin Heller.

  • Who are Jasper Therapeutics competitors?

    Competitors of Jasper Therapeutics include IDEXX, Particular Sciences and Althea.